Kent P. Friedman

Kent P. Friedman, MD
Assistant Professor of Radiology, Division of Nuclear Medicine
Section Chief, Division of Nuclear Medicine
660 First Avenue New York, NY 10016
Educational Details: 

2001 - University of Connecticut School of Medicine, M.D.

2002 - University of Connecticut School of Medicine

2004 - The Johns Hopkins Medical Institutions

2005 - The Johns Hopkins Medical Institutions

Research Interest: 

Dr. Friedman is a nuclear medicine physician with fellowship training in PET/CT. My current position is Section Chief for Nuclear Medicine, Department of Radiology at NYU Langone Medical Center (NYULMC). He is Coorganizer of the MR-PET Research Focus Group at NYULMC, providing guidance and leadership for the development of a large number of MR-PET research protocols conducted at NYULMC. Through his work with the MR-PET Research Group I am fostering collaborations with numerous investigators in the Radiology, Oncology, Radiation Oncology, Endocrinology, Surgery, Neurology and Psychiatry Departments.

His primary research interest focuses on how to combine multiple dynamically changing parameters measured on sequential mutimodality scans (PET/CT, SPECT/CT, PET/MR) to best diagnose disease and predict and monitor response to therapies. Projects supporting this general aim include an ongoing analysis of metabolic treatment responses in breast cancer patients, active work in PET and MR responses to anti-angiogenic therapy, and assessment of PET response assessment in radiation therapy among different tumor histologies and treatment regimens. Evaluation of PET lesion segmentation and quantitation techniques are part of this general research aim and also tie in to my work in my role as Chair of the Society of Nuclear Medicine and Molecular Imaging's Quality Assurance Committee. Specific experience in neurology research includes my role as co-investigator for 18F-based amyloid PET imaging and therapy trials. I am engaged in a study comparing the diagnostic accuracy of brain PET/MR compared to PET/CT and I am in Q4 2012 initiating protocols related to I-124 PET/MR imaging of thyroid cancer and multimodality PET/CT/MR assessment of treatment response in autologous immunotherapy for prostate cancer.

Selected Publications: 

1. Friedman K, Lee P, Sasso D, Thrall R and Weiner R: Localization mechanism of In-111 labeled antiintercellular adhesion molecule-1 in a bleomycin-induced rat model of lung injury. J Nucl Med 1997;38:191P.

2. Patel P, Somervell H, Friedman K, Barbu A, Zeiger M: Combined 99mTc SPECT/CT for preoperative localization in primary hyperparathyroidism. J Nucl Med 2004;45:289P.

3. Friedman K, Somervell H, Patel P, Melton GB, Garrett-Mayer E, Dackiw APB, Civelek AC, Zeiger MA: Effect of calcium channel blockers on the sensitivity of preoperative 99mTc-MIBI SPECT for hyperparathyroidism. Surgery. 2004 Dec;136(6):1199-204. PMID: 15657576

4. Melton GB, Somervell H, Friedman KP, Zeiger MA, Cahid Civelek A: Interpretation of 99mTc sestamibi parathyroid SPECT scan is improved when read by the surgeon and nuclear medicine physician together. Nucl Med Commun. 2005 Jul;26(7):633-8. PMID: 15942484

5. Lavely WC, Goetze S, Friedman KP, Leal JP, Zhang Z, Garret-Mayer E, Dackiw AP, Tufano RP, Zeiger MA, Ziessman HA.: Comparison of SPECT/CT, SPECT, and planar imaging with single- and dual-phase (99m)Tc-sestamibi parathyroid scintigraphy. J Nucl Med 2007 Jul;48(7):1084-9. PMID: 17574983

6. Probst S, Lee J, Tu T, Berman R, Friedman K. Tc-99m sestamibi SPECT/CT with volumetric reconstruction for radioguided occult lesion localization and surgical excision of melanoma metastasis Clin Nucl Med. 2010 Mar;35(3):165-7. PMID: 20173446

7. Blum M, Tiu S, Chu M, Goel S, and Friedman K. I-131 SPECT/CT Elucidates Cryptic Findings on Planar Whole Body Scans and Can Reduce Needless Therapy With I-131 in Post-Thyroidectomy Thyroid Cancer Patients. 2011 Thyroid Nov;21(11):1235-47. PMID: 22007920

8. Larkin A, Serulle Y, Wagner S, Noz ME, Friedman KP. Quantifying the increase in radiation exposure with SPECT/CT compared to SPECT alone for routine nuclear medicine examinations. Int J Mol Imaging. 2011;897202. PMID: 21755054; PMCID: PMC3132661

Research Projects: 

National Institute of Diabetes and Digestive and Kidney Diseases
Accurate Measurement of Renal Function in Cirrhosis
Role: Co-investigator

Avid Radiopharmaceuticals, Inc
An open label, parallel group, multicenter study, evaluating the safety and imaging characteristics of 18F-AV-
45 in healthy volunteers, patients with mild cognitive impairment (MCI) and patients with Alzheimer’s disease
Role: Co-Investigator

Bayer Schering Pharma
An open-label, non-randomized, multi-center study to optimize image assessment and evaluate the efficacy and safety of BAY 94-9172 (ZK 6013443) positron emission tomography (PET) for detection/exclusion of cerebral amyloid beta in patients with probable Alzheimer’s disease compared to healthy volunteers
Role: Co-Investigator


Latest Updates

05/10/2019 - 21:50
05/10/2019 - 21:23

Philanthropic Support

We gratefully acknowledge generous support for radiology research at NYU Langone Health from:
• The Big George Foundation
• Raymond and Beverly Sackler
• Bernard and Irene Schwartz

Go to top